Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: Rationale, design, and preliminary data - 05/08/11
, Katsuya Kajimoto, MD b, Kuniya Asai, MD c, Masayuki Mizuno, MD d, Yuichiro Minami, MD d, Michitaka Nagashima, MD d, Koji Murai, MD a, Ryo Muanakata, MD a, Dai Yumino, MD d, Tomomi Meguro, MD e, Masatoshi Kawana, MD f, Jun Nejima, MD g, Toshihiko Satoh, MD h, Kyoichi Mizuno, MD c, Keiji Tanaka, MD a, Hiroshi Kasanuki, MD i, Teruo Takano, MD cfor the ATTEND Investigatorsj
Résumé |
Acute heart failure syndromes (AHFS) are likely to increase in the future, and the high readmission rate of patients with AHFS is an important issue in Western countries. However, there are very few published epidemiological studies on AHFS in the Asia Pacific region. Because AHFS are heterogeneous, the characteristics, clinical profile, and management of AHFS should be clarified in an epidemiological study. The acute decompensated heart failure syndromes (ATTEND) registry is a prospective, observational, multicenter cohort study being performed in Japan and is the first epidemiological study of AHFS in the Asia Pacific region. This study is designed to investigate several aspects of AHFS as follows: (1) the registry allows patient-based data collection for precise evaluation of patient characteristics and short-term outcomes, including the readmission rate; (2) confirmation of clinical assessments can be performed, and new clinical assessments can be created; and (3) feedback allows the modification of guidelines for clinical management. The present report describes the clinical characteristics of patients with AHFS in Japan based on the preliminary data collected in this study, and the similarities and differences in characteristics of these patients compared with those in Western countries. Although most of the patient characteristics did not differ from those reported in Western studies, there are some unique findings in this study, including a high rate of treatment with carperitide (69.4%) and angiotensin II receptor blockers (53.9%) at discharge and a longer hospital stay (median 21 days). The ATTEND registry is designed to provide valuable information to clarify the characteristics of patients with AHFS to improve their management.
Le texte complet de cet article est disponible en PDF.Plan
Vol 159 - N° 6
P. 949 - juin 2010 Retour au numéro
Article précédent
- Rationale and design of a randomized clinical trial to assess the safety and efficacy of frequent optimization of cardiac resynchronization therapy: The Frequent Optimization Study Using the QuickOpt Method (FREEDOM) trial
- William T. Abraham, Daniel Gras, Cheuk Man Yu, Lisa Guzzo, Manish S. Gupta, on behalf of the FREEDOM Steering Committee f
- Real-world outcome from ST elevation myocardial infarction in the very elderly before and after the introduction of a 24/7 primary percutaneous coronary intervention service
- Rhidian J. Shelton, Andrew M. Crean, Kathryn Somers, Claire Priestley, Carol Hague, Jonathan M. Blaxill, Stephen B. Wheatcroft, James M. McLenachan, John P. Greenwood, Daniel J. Blackman
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?